Lessening the severity and impact of influenza — dr. gregg C sylvester, MD — chief health officer, CSL seqirus.

Dr. Gregg Sylvester, MD is Chief Health Officer and Vice President, Medical Affairs, at CSL Seqirus (https://www.cslseqirus.us/our-company/leadership/gregg–… one of the world’s largest influenza vaccine companies.

Dr. Sylvester has led CSL Seqirus Medical Affairs since 2016, overseeing the global team that scientifically differentiates company’s vaccines by generating Real World Evidence and presenting CSL Seqirus research to national vaccine recommending organizations.

Dr. Sylvester has extensive experience in the pharmaceutical industry, government and patient care.

Prior to joining CSL Seqirus, Dr. Sylvester led Medical Affairs teams at Pfizer and Merck involved in the worldwide launches of vaccines including Gardasil (Human Papillomavirus Vaccine), Prevnar 13 (Pneumococcal Conjugate Vaccine) and Trumenba (Meningococcal Group B Vaccine).

Microbes, Ecology And Medicine — Dr. Sean M. Gibbons, Ph.D. — Associate Professor, Institute for Systems Biology (ISB)

Dr. Sean Gibbons, Ph.D. is Associate Professor at the Institute for Systems Biology (ISB — https://isbscience.org/people/sean-gibbons-phd/?tab=biography where his lab investigates how the structure and composition of evolving ecological networks of microorganisms change across environmental gradients, with a specific focus on how ecological communities in the gut change and adapt to individual people over their lifespans (i.e. host genotype, host development and host behavior) and how these changes impact human health (https://gibbons.isbscience.org/). His lab develops computational and experimental tools for investigating host-associated microbial communities to explore the interactions between ecology, evolution and ecosystem function, applying these insights to develop personalized interventions for improving human health and well-being.

Dr. Gibbons received his PhD in biophysical sciences from the University of Chicago in 2015, dual-advised by Jack Gilbert and Maureen Coleman. His graduate work focused on using microbial communities as empirical models for testing ecological theory.

Dr. Gibbons completed his postdoctoral training in Eric Alm’s laboratory in the Department of Biological Engineering at MIT from 2015–2018. His postdoctoral work focused on developing techniques to quantify individual-specific eco-evolutionary dynamics within the human gut microbiome.

Dr. Gibbons was awarded a Fulbright Graduate Fellowship to study microbiology and synthetic biology at Uppsala University in Sweden, where he earned a master’s degree in 2010. His PhD work was supported by an EPA STAR Graduate Fellowship. Upon joining the ISB faculty in 2018, his startup package was supported, in part, by a Washington Research Foundation Distinguished Investigator Award.

Controlling Sepsis, ARDS And Other Life Threatening Inflammatory Diseases — Prof. Dr. Niels Riedemann, MD, Ph.D. — CEO, InflaRx

Prof. Dr. Niels Riedemann, MD, Ph.D. is Chief Executive Officer and Founder of InflaRx (https://www.inflarx.de/Home/About-Inflarx/Team~Niels-C.-Riedemann~.h… a biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR inhibitors to the treatment of life-threatening or debilitating inflammatory diseases with high unmet medical need.

Prof. Dr. Riedemann has over 15 years of experience in the biotech industry and drug development, as well as over 20 years of experience in complement immunology research. He founded InflaRx in 2007 and has served as Chief Executive Officer since inception of the company. He has been instrumental in and led numerous private and public financing rounds of the company and has been the responsible lead for its Nasdaq IPO in 2017. He is named inventor on several internationally granted core patents of InflaRx.

As physician, Prof. Dr. Riedemann was appointed Vice Director (“Leitender Oberarzt”) of Intensive Care Medicine, and led a 50-bed University ICU unit for over 6 years at Friedrich Schiller University, Jena, Germany until 2015. Before that, he received his board certification as General Surgeon upon completion of his surgical fellowship at MHH (Hannover Medical School, Germany) in 2007 where he also received his habilitation (equivalent to Ph.D.) and where he still holds an Adjunct Professorship (APL Professor). He spent three years as postdoctoral research fellow at the University of Michigan, USA until 2003. He received his medical training at Albert Ludwig University (ALU), Freiburg, Germany, and Stanford University, USA and graduated as Dr. med. (equivalent to M.D.) from ALU in 1998.

Prof. Dr. Riedemann’s research has been awarded with several national and international awards. He has received extensive extra-mural funding and published over 60 peer reviewed scientific publications in highly ranked journals. He has served as a member on a Board of Directors and a Scientific Advisory Board of two large scientific governmental funded programs. He currently serves as Co-Chair of the Health Politics working group of Bio-Deutschland and he serves as member of the board of trustees for the German Sepsis Foundation.

Curing Cancer In A Flash — Dr. Bill Loo, Jr., MD, PhD — Professor, Stanford Medicine / Co-Founder, TibaRay Inc

Dr. Billy W. Loo Jr., MD PhD (https://med.stanford.edu/profiles/6839) is a Professor of Radiation Oncology, a member of the Stanford Cancer Institute, the Molecular Imaging Program at Stanford (MIPS), and of Bio-X Interdisciplinary Biosciences Institute. He is a physician-scientist Radiation Oncologist and Bioengineer who directs the Thoracic Radiation Oncology Program and is Principal Investigator of the FLASH Sciences Lab at Stanford (https://med.stanford.edu/loo-lab.html).

Dr. Loo’s clinical specialty is precision targeted radiotherapy for lung/thoracic cancers, including stereotactic ablative radiotherapy (SABR). Dr. Loo is a recognized expert in thoracic cancers serving on multiple national committees (including as writing member or vice-chair) that publish clinical guidelines on the treatment of lung cancer and other thoracic malignancies, particularly the National Comprehensive Cancer Network (NCCN).

Dr. Loo’s clinical research is in clinical trials and implementation of new treatment techniques for lung cancer, and development of new medical imaging methods for measuring organ function and predicting response to cancer treatment. He also has developed novel applications of SABR including treatment of pulmonary emphysema and cardiac arrhythmias.

The research focus of the FLASH Sciences Lab at Stanford, directed by Dr. Loo, is the development and study of extremely rapid FLASH therapy to optimize the biological therapeutic index of cancer radiotherapy, and the technological infrastructure for this basic research and its clinical translation.

Health, vitality and longevity through bioengineering — kevin caldwell — CEO, ossium health.

Kevin Caldwell is CEO, Co-Founder & President of Ossium Health (https://ossiumhealth.com/), a commercial stage bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects.

Mr. Caldwell built Ossium from a small startup into the clinical stage bioengineering company it is today, setting the company’s mission to improve human health through bioengineering and designed its platform-based model for cellular therapeutics development. He has led the company’s successful pursuit, negotiation, and execution of more than 50 business relationships, including 5 successful fundraisings and dozens of supply partnerships, clinical partnerships, and commercial contracts with biopharmaceutical companies.

After seven years of strategic engagement and networking, Mr. Caldwell drove the team to successfully secure a transformative federal contract with BARDA (Biomedical Advanced Research and Development Authority) that validates Ossium’s innovative approach. This milestone represents the culmination of persistent relationship-building, targeted proposals, and unwavering commitment to addressing national biomedical challenges through cutting-edge technology and collaborative partnerships.

Prior to founding Ossium, Mr. Caldwell served as an Engagement Manager at McKinsey’s San Francisco office where he advised clients in the biotechnology and healthcare sectors. His projects ranged from due diligence of acquisition targets in the biotech startup ecosystem to restructuring distressed biopharma companies. Mr. Caldwell led more than 20 engagements with more than a dozen clients, leading teams that advised clients on revenue growth, go to market strategy, and organizational restructuring.

Environmental Gerontology & Vulnerability Science For Health And Well-Being — Dr. Amir Baniassadi, Ph.D. — Marcus Institute for Aging Research, Hebrew SeniorLife / Harvard Medical School.

Dr. Amir Baniassadi, Ph.D. is an Instructor of Medicine at Harvard Medical School and an Assistant Scientist in Marcus Institute for Aging Research (https://www.marcusinstituteforaging.o… where he works on environmental impacts on health and well-being of older populations.

Dr. Baniassadi works on the impacts of ambient air temperature and air quality (both indoors and outdoors) on outcomes related to the health and well-being of physiologically and socioeconomically vulnerable populations. His research applies novel environmental modeling and measurement techniques along with remote and long-term physiological and functional monitoring of individuals to establish relationships between exposure and outcome variables of interest outside clinical lab settings. The ultimate goal of his research is to develop environmental interventions that optimize the environment for health and longevity of older adults.

Dr. Baniassadi has a Ph.D. in Civil, Environmental, and Sustainable Engineering from Arizona State University and a B.Sc. degree in Mechanical Engineering from the University of Tehran. His post-doctoral training includes a three-year T32 fellowship in Translational Research in Older adults, and a two-year postdoctoral fellowship at Harvard University Graduate School of Design.

#AmirBaniassadi #HarvardMedicalSchool #MarcusInstituteForAgingResearch #EnvironmentalGerontology #VulnerabilityScience #Exposome #Health #WellBeing #Wearables #SmartHome #AgingInPlace #Thermoregulation #HeatIslands.

Crowdsourcing treatments that work — yael elish — CEO & founder, stuffthatworks.

Yael Elish is CEO and Founder of StuffThatWorks (https://www.stuffthatworks.health/), a company that offers an online platform where people suffering from chronic diseases can share information to learn which treatments work best for their specific condition, based on the experience of their peers combined with a smart, AI-based crowdsourcing system.

A passionate entrepreneur with expertise in crowdsourcing and consumer-facing products, Yael was on the Waze founding team, where she drove the overall product strategy that led the company from User One to one of the world’s most notable crowdsourcing endeavours. She also co-founded eSnips and NetSnippet, and was part of the senior management team that took Commtouch to its successful NASDAQ IPO in 2000.

Prior to Commtouch, Yael led the sales and marketing efforts for various start-ups in Israel.

Yael holds a first degree in Foreign Relations from the Hebrew University of Jerusalem, Israel.

Revolutionizing the fight against brain cancers — dr. thomas chen MD, phd, FAANS, — CEO/CSO, neonc technologies holdings inc.

Dr. Thomas Chen, MD, Ph.D. is Founder, CEO & CSO, and Board Director, of NeOnc Technologies (https://neonc.com/), a developer of a proprietary, patented platform technology that can potentially transport pharma-based therapeutics directly to the brain without the normal boundary restrictions imposed by the body’s Blood-Brain Barrier (BBB), providing patients with potentially more effective treatments.

NeOnc is developing a portfolio of treatments for brain cancer and other central nervous system (CNS) disorders.

Dr. Chen is a board-certified neurosurgeon and the Director of Surgical Neuro-Oncology at USC where he is also a tenured Professor of Neurosurgery and Pathology (https://keck.usc.edu/faculty-search/thomas-c-chen/).

Dr. Chen graduated summa cum laude from the University of Illinois at Urbana-Champaign, where he also received Bronze Tablet honors and was inducted into the Phi Beta Kappa national academic honor society. He attended the University of California, San Francisco, where he obtained his MD, and was inducted into the Alpha Omega Alpha National Medical Honor Society. He underwent neurosurgery training at USC and obtained a Ph.D. degree in pathobiology where his thesis was on the role of immunotherapy in malignant brain tumors.

BIG Projects To Solve Pressing Issues In Science — Dr. Christopher Stubbs, Ph.D. — Professor of Physics and Astronomy, Harvard University.

Dr. Christopher Stubbs, Ph.D. is the Samuel C. Moncher Professor of Physics and Astronomy, and has recently served as the Dean of Science in the Faculty of Arts and Sciences, at Harvard University (https://astronomy.fas.harvard.edu/peo…

Dr. Stubbs is an experimental physicist working at the interface between particle physics, cosmology and gravitation. His interests include experimental tests of the foundations of gravitational physics, searches for dark matter, characterizing the dark energy, and observational cosmology.

Dr. Stubbs was a member of one of the two teams that first discovered dark energy by using supernovae to map out the history of cosmic expansion.

Dr. Stubbs is currently heavily engaged in the construction of the Large Synoptic Survey Telescope (LSST), for which he was the inaugural project scientist. He founded the APOLLO collaboration that is using lunar laser ranging and the Earth-Moon-Sun system to probe for novel gravitational effects that may result from physics beyond the standard model.

Harnessing The Power Of The Crowd To Solve Important Problems — Steve Rader — Program Manager — Center of Excellence for Collaborative Innovation & Tournament Lab, NASA.

Steve Rader (https://www.nasa.gov/people/steve-rader /) serves as the Program Manager of NASA’s Center of Excellence for Collaborative Innovation (CoECI — https://www.nasa.gov/coeci/) and the NASA Tournament Lab (NTL — https://www.nasa.gov/general/nasa-tou…), which are working to infuse challenge and crowdsourcing innovation approaches at NASA and across the federal government. CoECI focuses on the study and use of curated, crowdsourcing communities that utilize prize and challenge-based methods to deliver innovative solutions for NASA and the U.S. government.

In 2015, Steve was named as one of 20 Challenge Mentors for U.S. Government Services Administration’s (GSA) Prizes and Challenges government-wide community of practice. Steve has worked with various projects and organizations to develop and execute over 100 different challenges. He speaks regularly about NASA’s work in crowd-based challenges and the future of work both publicly and internally to the NASA workforce to promote the use of open innovation tools.

Steve has a Mechanical Engineering degree from Rice University and has worked at NASA’s Johnson Space Center for 33 years. Prior to joining CoECI/NTL, Steve worked in mission control, flight software development for the Space Shuttle and International Space Station, command and control systems development for the X-38 (the experimental re-entry vehicle designed by NASA to research a possible emergency crew return vehicle), and led the Command, Control, Communications, \& Information (C3I) architecture definition for the Constellation Program.

#SteveRader #NASA #CenterOfExcellenceForCollaborativeInnovation #TournamentLab #OpenInnovation #GovernmentServicesAdministration #Prizes #Challenges #MechanicalEngineering #X38 #ConstellationProgram #JohnsonSpaceCenter #SpaceShuttle #InternationalSpaceStation #Crowdsourcing #DualUse #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast